<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584659</url>
  </required_header>
  <id_info>
    <org_study_id>iBLAD2018</org_study_id>
    <nct_id>NCT03584659</nct_id>
  </id_info>
  <brief_title>Patient-reported Outcomes in Bladder Cancer</brief_title>
  <acronym>iBLAD</acronym>
  <official_title>Patient-reported Outcomes in Bladder Cancer; a Multicentre Randomized Controlled Trial: The iBLAD Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electronic reporting of patient-reported outcomes with alert algorithm will be tested in a
      randomized trial in bladder cancer patients undergoing chemo- or immunotherapy. The clinical
      endpoints will be:

        -  Quality of life

        -  Completion of treatment

        -  Hospital admission

        -  Dose reductions

        -  Survival
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bladder cancer is in Europe the 4th most incident cancer among men and the 7th most frequent
      cause of cancer death. Many patients will receive chemo- or immunotherapy in either the
      neoadjuvant setting or for recurrent or metastatic disease. The registration and handling of
      side effect is crucial in bladder cancer treatment, since the missing identification and
      insufficient treatment of such can lead to incomplete treatment and thereby decreased effect.
      It is therefore of utmost importance to develop new tools which can increase identification
      of the side effects and improve treatment to secure the best life expectancies for these
      patients.

      This study will in a randomized trial using PRO-CTCAE™ questions, EORTC QLQ-C30 + QLQ-BLM30
      in one arm versus standard procedure regarding side effect registration and handling in the
      other arm, test the effect of electronic reporting of side-effects and quality of life with a
      specifically developed alert-algorithm. Both study arms will include chemotherapy and
      immunotherapy patients as standard therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of completion of treatment</measure>
    <time_frame>Within the first 6 months of treatment</time_frame>
    <description>Registration of whether patients complete the planned treatment and if not if the cessation was preventable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital admission</measure>
    <time_frame>Within the first 6 months of treatment</time_frame>
    <description>Registration of whether patients by closer contact to clinic between visits can decrease the rate of hospital admissions for preventable causes during treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaires EORTC QLQ-C30 (general quality of life questionnaire) and EORTC QLQ-BLM30(quality of life questionnaire specifically for muscle-invasive bladder cancer patients)</measure>
    <time_frame>Within the first 6 months of treatment</time_frame>
    <description>Registration of differences in quality of life between the two arms in the study. EORTC QLQ-C30(scale range 0-100, a higher score indicating better quality of life) and QLQ-BLM30(scale range 0-100, a higher score indicating increase in symptom burden) will be used for as quality of life measurement. The scores will be presented graphically in separate figures. The EORTC QLQ-BLM30 cannot be applied without the QLQ-C30, hence the aggregation of measures in the present outcome measure category.
Differences between the two arms will be tested using t-test and analysis of covariance (ANCOVA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival measured from time of study initiation to death</measure>
    <time_frame>Analysis will be made up to 2 years after study completion</time_frame>
    <description>Differences in median overall survival and analysis of survival differences between the intervention-arm and the standard of care arm. The analysis will be carried out with log-rank analysis and Kaplan-Meier curves. The analysis will be carried out separately for chemotherapy and immunotherapy recipients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-reductions</measure>
    <time_frame>Within the first 6 months of treatment</time_frame>
    <description>Registration of differences in number of dose reductions of chemotherapy between the two arm in the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will continue standard procedure regarding side effect registration and handling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be assigned to intervention by weekly electronic reporting of side effects and quality of life. A specifically developed alert-algorithm will in real-time guide both patient and alert clinical staff if symptoms are increasing or quality of life is deteriorating.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electronic patient-reported outcomes</intervention_name>
    <description>Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.</description>
    <arm_group_label>PRO</arm_group_label>
    <other_name>Alert-algorithm</other_name>
    <other_name>Real-time guidance of patients when symptom reporting</other_name>
    <other_name>Alerts to clinical staff</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Urothelial carcinoma

          -  Initiating chemo- or immunotherapy

          -  No serious cognitive deficits

          -  Read and understand Danish

          -  Assigned electronic communication with health services with &quot;E-boks&quot;

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gry Assam Taarnhøj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gry Assam Taarnhøj, MD</last_name>
    <phone>+45 35450737</phone>
    <email>gry.assam.taarnhoej@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helle Pappot, MD, DMSc</last_name>
    <phone>+45 35455013</phone>
    <email>helle.pappot@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Carus, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gry Assam Taarnhøj, MD</last_name>
      <phone>+45 51943003</phone>
      <email>gry.assam.taarnhoej@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Helle Pappot, MD, DMSc</last_name>
      <email>helle.pappot@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Oncology</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henriette Lindberg, MD, PhD</last_name>
      <email>henriette.lindberg@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Line Hammer Dohn, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rikke Hedegaard Dahlrot, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Helle Pappot</investigator_full_name>
    <investigator_title>Clinical Oncologist, Consultant, DMSc</investigator_title>
  </responsible_party>
  <keyword>Patient-reported outcomes</keyword>
  <keyword>Electronic reporting of symptoms</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

